SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
April 16, 2012
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of incorporation)
||(Commission File Number)
||(I.R.S. Employer Identification No.)|
7400 Paseo Padre Parkway
Fremont, CA 94555
|(Address of principal executive offices)
Registrant’s telephone number, including
area code: (510) 651-4450
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
On April 16, 2012, WaferGen Bio-systems,
Inc. (the “Company”) issued a press release announcing a strategic realignment and new direction for the organization.
The Company's focus will be to enable customers to perform accurate high-throughput qPCR projects for gene expression, genotyping,
and target enrichment for next-generation sequencing in a simpler and more cost-effective way. Underlying this strategy is
a new version of the Company's SmartChip System that will allow customers to design and execute their own experiments in an “open
format.” In conjunction with its new strategic direction, the Company announced a consolidation and reorganization
of its operations. The restructuring plan has resulted in the elimination of approximately 20 positions during the current fiscal
quarter, as well as other cost-saving measures.
A copy of the press release issued by the
Company is furnished hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
||Press release issued on April 16, 2012|
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
WaferGen Bio-systems, Inc.
|Date: April 16, 2012
||/s/ John Harland|
||Interim Chief Financial Officer|